- EF Hutton has initiated coverage of Bionano Genomics Inc (NASDAQ:BNGO) with a Buy rating and a price target of $1.75.
- The analyst says Bionano Genomics’s optical genome mapping (OGM) platform is well-positioned to disrupt cytogenetic analysis with its ability to reliably and efficiently detect Structural Variants (SV) across a comprehensive range of resolutions that existing techniques do not.
- BNGO targets a global market of 10,000 cytogenetic labs that analyze roughly 10 million DNA samples yearly in BNGO’s disclosed target indications.
- OGM adoption remains in the early innings, as BNGO has a global installed base of 259 Saphyr sequencers.
- The analyst says that the ongoing investments in clinical validation studies will ultimately underpin the inclusion of OGM workflows into clinical practice guidelines, functioning as additional catalysts for adoption.
- The analyst also notes that Bionano Genomics is in the process of releasing its next-generation, high-throughput OGM platform, which is expected to increase throughput by 13x over its current system.
- It expects that BNGO’smulti-pronged reimbursement efforts will be sufficient to support the company’s near- to intermediate-term growth expectations.
- Price Action: BNGO shares are down 2.90% at $0.65 on the last check Thursday.
Oxbridge Re Considering A Full Range Of Strategic Alternatives For The Co, And/ Or Its Web-3 Division Subsidiary SurancePlus Holdings, Including A Sale, Spinout, Merger, Divestiture, Recapitalization, And Other Strategic Transactions, Or Continuing To…
Oxbridge Re Holdings Limited (NASDAQ: OXBR), (the "Company"), together with its subsidiaries is engaged in the business of tokenized Real-World Assets ("RWAs") initially in the form of tokenized reinsurance securities,
